8-K: Anixa Biosciences Expands Cancer Vaccine Partnership with Cleveland Clinic

Anixa Biosciences has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types, expanding their existing collaboration.

Summary

• Anixa Biosciences and the Cleveland Clinic Foundation have entered into a Joint Development and Option Agreement to collaborate on developing cancer vaccines.
• Anixa will pay a non-refundable option fee to Cleveland Clinic by May 23, 2024.
• Anixa will also provide development funding in three tranches, with payments due on May 8, 2024, January 31, 2025, and January 31, 2026.
• The agreement is effective from May 3, 2024, and will last for 36 months or until the completion of the work plan.
• Anixa has the option to license any inventions arising from the collaboration, subject to certain terms and conditions.
• Cleveland Clinic retains the right to use the licensed patents for research and educational purposes.
• The new agreement expands on existing collaborations between Anixa and Cleveland Clinic on breast and ovarian cancer vaccines.
• The new vaccines will target retired proteins found in specific cancers, aiming to destroy cancer cells as they arise.
• The research will be led by Dr. Thaddeus Stappenbeck and Dr. Justin Johnson at Cleveland Clinic.
• Anixa's CEO, Dr. Amit Kumar, will present an overview of the company and its programs at the Sidoti Micro-Cap Virtual Conference on May 9, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the expansion of a promising partnership and the potential for novel cancer vaccine development. The company is also seeking to maintain its lead in the retired protein antigen cancer research arena.

Positives

• The agreement expands Anixa's partnership with Cleveland Clinic, a leading research institution.
• The collaboration focuses on a novel scientific mechanism for cancer vaccines.
• The agreement includes an option for Anixa to license any resulting inventions.
• The company has promising preliminary data from its existing breast cancer vaccine program.
• The company is seeking to maintain its lead in the retired protein antigen cancer research arena.

Negatives

• Anixa is required to pay a non-refundable option fee and development funding in tranches.
• The agreement can be terminated by either party under certain conditions.
• Anixa will lose its option in connection with a terminated statement of work.
• The company is reliant on the success of clinical trials and research.

Risks

• The development of cancer vaccines is subject to significant risks and uncertainties.
• Clinical trials may not yield positive results.
• The company may not be able to successfully commercialize the vaccines.
• The agreement can be terminated by either party under certain conditions.
• The company is reliant on the success of clinical trials and research.

Future Outlook

Anixa expects to expand its cancer vaccine program with Cleveland Clinic, targeting various cancer types using the same technology platform. The company believes the search for retired protein antigens will be pursued by many cancer researchers and they are seeking to maintain their lead in this area.

Management Comments

• Anixa Chairman and CEO Dr. Amit Kumar stated, 'Cleveland Clinic is a valued partner to Anixa in the development of both breast and ovarian cancer vaccines.'
• Dr. Kumar also stated, 'The progress we've made to date in the breast cancer vaccine program, including promising preliminary data, drives our confidence in pursuing research and development for additional vaccines and cancer types using the same technology platform.'
• Dr. Stappenbeck said, 'We look forward to expanding our relationship with Anixa in this endeavor.'

Industry Context

This announcement aligns with the growing interest in cancer immunotherapy and vaccine development. The focus on retired proteins represents a novel approach in the field. The collaboration between a biotech company and a major research institution is a common model in the industry.

Comparison to Industry Standards

• The collaboration between Anixa and Cleveland Clinic is similar to other partnerships between biotech companies and research institutions, such as Moderna's collaboration with the National Institutes of Health for vaccine development.
• The focus on retired proteins is a novel approach, differentiating Anixa from companies using more traditional vaccine technologies.
• The development of vaccines for multiple cancer types is a common goal in the industry, with companies like BioNTech and Gritstone Bio also pursuing similar strategies.
• The use of a Phase 1 clinical trial for triple negative breast cancer is a standard approach for early-stage vaccine development, similar to trials conducted by other companies in the field.

Stakeholder Impact

• Shareholders may view the agreement positively due to the potential for new revenue streams and advancements in cancer treatment.
• Employees may be motivated by the company's expansion and focus on innovative research.
• Patients may benefit from the development of new cancer vaccines.
• Cleveland Clinic will benefit from the funding and potential royalties.

Next Steps

• Anixa will pay the option fee by May 23, 2024.
• Anixa will make the first development funding payment on May 8, 2024.
• Cleveland Clinic will conduct research under the new agreement.
• Anixa will present at the Sidoti Micro-Cap Virtual Conference on May 9, 2024.
• The company will evaluate which cancer types will be best for targeting.

Key Dates

Keywords

cancer vaccines, Anixa Biosciences, Cleveland Clinic, joint development agreement, retired proteins, immunotherapy, clinical trials, biotechnology, oncology, breast cancer, ovarian cancer